Sector News

Novartis buys 12.8 percent stake in BioLineRX in co-development deal

December 17, 2014
Life sciences
(Reuters) – Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.
 
Under the agreement, Novartis, which invested an initial $10 million, will evaluate projects presented by BioLineRX for development and future licensing, the Israeli firm said in a statement. They hope to develop up to three clinical projects.
 
Novartis acquired an initial 5 million American depositary shares of BioLineRx in a private transaction at $2.00 a share.
 
The partnership will be transformative for BioLineRX, said Chief Executive Kinneret Savitsky, and will give Novartis, one of the world’s largest pharmaceutical companies, access to Israeli research institutions, hospitals and biotech start-ups.
 
Once a project is selected, Novartis will pay BioLineRx an option fee of $5 million and fund half the remaining development costs in the form of an additional equity investment in BioLineRx.
 
The companies agreed to limit how big a share Novartis can buy of BioLineRX, but the amount was not disclosed, a BioLineRX spokeswoman said.
 
Novartis will have an exclusive right of first negotiation to license from BioLineRx each project.
 
(Reporting by Ari Rabinovitch; Editing by Tova Cohen and David Holmes)

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]